drugset / Trial / NCT04412616
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2025-12-01
- Completion
- 2026-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZZ06 | Unknown | 0.03 mg/kg | — |
| Subject | ZZ06 | Unknown | 0.06 mg/kg | — |
| Subject | ZZ06 | Unknown | 0.12 mg/kg | — |
| Subject | ZZ06 | Unknown | 0.22 mg/kg | — |
| Subject | ZZ06 | Unknown | 0.39 mg/kg | — |
| Subject | ZZ06 | Unknown | 0.7 mg/kg | — |
| Subject | ZZ06 | Unknown | 1 mg/kg | — |
Indications
No indication recorded.